It has been shown that cholinesterase (CHE) responds to chemotherapy in advanced gastric cancer.22 Findings have demonstrated low serum CHE levels to be a significant predictor of poor prognosis for patients with intermediate to advanced HCC undergoing treatment with sorafenib.23,24. Here, BCHE is linked to hepatocellular carcinoma.